• Sustainability
  • DE&I
  • Pandemic
  • Finance
  • Legal
  • Technology
  • Regulatory
  • Global
  • Pricing
  • Strategy
  • R&D/Clinical Trials
  • Opinion
  • Executive Roundtable
  • Sales & Marketing
  • Executive Profiles
  • Leadership
  • Market Access
  • Patient Engagement
  • Supply Chain
  • Industry Trends

Daiichi Sankyo Closes Indian Research Division


January 18, 2017

Daiichi Sankyo has closed its Mumbai, India research division as part of the company’s strategy to narrow its focus to cancer research, India's Economic Times reports.   The Daiichi Sankyo India Pharma Limited (DSIN) was established in 2007 and employs about 170 people, mainly engaged in conducting drug discovery research targeting infectious diseases and inflammation.   Following its closure, the DSIN R&D pipeline will be transferred to Daiichi Sankyo’s R&D Division.    http://economictimes.indiatimes.com/industry/healthcare/biotech/pharmaceuticals/daiichi-shuts-india-rd-division/articleshow/56486750.cms

Related Videos